KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Non-Current Assets (2016 - 2025)

CRISPR Therapeutics AG's Non-Current Assets history spans 11 years, with the latest figure at $279.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 8.31% year-over-year to $279.6 million; the TTM value through Dec 2025 reached $1.2 billion, down 5.98%, while the annual FY2025 figure was $279.6 million, 8.31% down from the prior year.
  • Non-Current Assets for Q4 2025 was $279.6 million at CRISPR Therapeutics AG, down from $316.2 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $420.7 million in Q3 2022 and bottomed at $125.6 million in Q1 2021.
  • The 5-year median for Non-Current Assets is $320.4 million (2023), against an average of $316.6 million.
  • The largest annual shift saw Non-Current Assets soared 244.29% in 2021 before it fell 22.44% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $334.4 million in 2021, then rose by 16.65% to $390.0 million in 2022, then fell by 17.57% to $321.5 million in 2023, then decreased by 5.16% to $304.9 million in 2024, then decreased by 8.31% to $279.6 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Non-Current Assets are $279.6 million (Q4 2025), $316.2 million (Q3 2025), and $296.0 million (Q2 2025).